I never said the conference wasn't worthwhile - just that 1AD shouldn't be attending. It is a pointless exercise for them to continually pedal the same pre-clinical story until they have some hard data. The story is 'known' - it just isn't being 'bought' atm. And it annoys we that they are doing so so soon after a somewhat botched capital raising. On reflection I'll stick with naive indignation.
1AD Price at posting:
20.5¢ Sentiment: None Disclosure: Held
